JCJessie R. Chung

Jessie R. Chung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jessie R. Chung has a total of 336 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Potential impact of changes in influenza vaccination coverage and effectiveness on pediatric influenza burden in the United States, 2022/23–2024/25

    by Sinead E. Morris, Sarabeth M. Mathis, Jessie R. Chung, Jennifer DeCuir, Samantha M. Olson, Sascha Ellington, Alissa O’HAlloran, Dawud Ujamaa, Catherine H. Bozio, Anurag Jain, et al.

    Background and Objectives: Influenza vaccination has a strong safety record and is effective in reducing pediatric influenza-associated morbidity and mortality. However, pediatric vaccination coverage (VC) has declined since the 2019/20 influenza season in the United States. We estimated the impact of increased vaccine protection (through increased VC and/or vaccine effectiveness [VE]) on pediatric influenza-associated burden during the 2022/23–2024/25 seasons. Methods: We used a compartmental model and laboratory-confirmed influenza-associated hospitalization, VC, and VE data among children 6 months–17 years to estimate influenza burden from 2022/23–2024/25 (the ‘baseline’ scenario) and the impact of vaccination. We simulated scenarios that (1) increased VC by five percentage points; (2) increased VE by five percentage points; (3) increased VC and VE by five percentage points; and (4) increased VC to levels achieved in 2019/20 (the season with the highest pediatric VC to date). We estimated the difference in hospitalizations and deaths between each scenario and the baseline scenario. Results: Among children 6 months–17 years, an estimated 120,000 influenza-associated hospitalizations and 1,650 deaths occurred across all seasons at baseline. Increasing VC to 2019/20 levels had the greatest estimated impact, reducing hospitalizations by 8,670 (7.2%) and deaths by 130 (7.9%). Increasing both VC and VE by five percentage points reduced hospitalizations by 6.6% and deaths by 6.7%, whereas increasing VC or VE by five percentage points reduced hospitalizations by 3.1% and deaths by 3.2%. Conclusions: Increasing pediatric influenza vaccination coverage back to 2019/20 levels was estimated to significantly reduce pediatric influenza-associated morbidity and mortality. What’s known on this subject: Pediatric influenza vaccination coverage has declined in the United States since the 2019/20 influenza season despite its effectiveness and strong safety record. The impact of this decline on influenza-associated morbidity and mortality has not been quantified. What this study adds: We estimated pediatric influenza-associated outcomes in the 2022/23–2024/25 influenza seasons under different scenarios that increased vaccination coverage and/or effectiveness. We estimated the greatest reductions in influenza-associated hospitalizations and deaths (7.2% and 7.9%, respectively) if coverage remained at 2019/20 levels.

  • Open Access

    Comparison of Influenza Vaccine Effectiveness Estimates Using Test-Negative Prospective Enrollment and Electronic Health Record Data, United States, 2024—2025

    by Ashley M. Price, Callie McLean, Seana Cleary, Aleda M. Leis, Ivana A. Vaughn, Stacey L. House, Sam Ellsworth, Krissy Moehling Geffel, Louise H. Taylor, Manjusha Gaglani, et al.

    Background: Influenza vaccine effectiveness (VE) is assessed annually through prospective enrollment of patients presenting with acute respiratory symptoms in a test-negative study design. Influenza VE has also been estimated from electronic health record (EHR) databases by linking medical diagnoses, laboratory test results, and patient influenza vaccination. There are limited data on agreement between influenza VE estimates from prospective enrollment versus EHR databases. Methods: The US Influenza Vaccine Effectiveness Network prospectively enrolled outpatients meeting clinical screening criteria and collected respiratory specimens to determine influenza virus infection. Seven study sites also identified EHR databases that included diagnostic codes for outpatient encounters associated with medically attended acute respiratory illness (MAARI), clinical respiratory virus testing, and influenza vaccination status. Effectiveness of influenza vaccination against laboratory-confirmed influenza was estimated from both data sources using logistic regression models including patient age, study site, and month of illness as 100(%) x (1 − adjusted odds ratio), comparing influenza vaccination among laboratory-confirmed influenza-positive patients versus laboratory-confirmed influenza-negative patients. Results: From October 2024—April 2025, 2,016 (30%) of 6,793 prospectively enrolled patients and 75,885 (24%) of 282,444 EHR MAARI encounters had laboratory-confirmed influenza virus infection. Effectiveness of vaccination against laboratory-confirmed influenza was 36% (95% confidence interval [CI]: 26–44) among prospectively enrolled patients and 38% (95% CI: 36–39) among EHR MAARI encounters. Comparing influenza VE estimates from the two data sources, confidence intervals overlapped for all age groups except for adults aged ≥65 years: -3% (95% CI: -53–30) among prospective enrollment versus 35% (95% CI: 32–39) VE from EHR MAARI encounters. Conclusion: Overall, influenza VE estimates from retrospective EHR data were similar to VE estimates using the test-negative design with prospective enrollment. The age group-specific differences in estimated VE observed in US adults aged ≥65 years compared with younger age groups merit further investigation.

  • Influenza Antibody Levels Associated With Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu Vaccine Effectiveness Network, November 2018 to May 2019

    by Brendan Flannery, Jessie R Chung, Crystal Holiday, Stacie Jefferson, Manjusha Gaglani, Kempapura Murthy, Richard K Zimmerman, Mary Patricia Nowalk, Michael L Jackson, Karen J Wernli, et al.

    Background: We assessed associations between antibody concentrations within 7 days of symptom onset and testing positive for influenza virus infection among outpatients enrolled in a test-negative study. Methods: From November 2018 to May 2019, study sites in 5 states obtained serum and respiratory specimens from outpatients aged ≥18 years presenting with acute respiratory illness. Respiratory specimens were tested for influenza virus, and viral clades were identified by means of genomic sequencing. We measured influenza antibody titers against vaccine and circulating viruses by means of hemagglutination inhibition (HI), microneutralization (MN) and neuraminidase inhibition (NAI) assays. Reduction in the odds of influenza-associated illness at increasing HI, MN, and NAI antibody titers was estimated using logistic regression, adjusting for influenza vaccination status and time since the beginning of influenza season. Results: Among 175 patients with influenza virus infection, including 112 with influenza A(H1N1)pdm09 and 63 with A(H3N2) (44 clade 3C.3a), and 130 test-negative control patients, higher HI, MN, and NAI antibody titers against circulating influenza viruses were associated with lower odds of confirmed influenza. The odds of A(H1N1)pdm09 infection were 44% and 54% lower for each 2-fold increase in A(H1N1)pdm09 HI or NAI titer, respectively. The odds of A(H3N2) infection were 49% and 28% lower, respectively, for each 2-fold increase in MN or NAI titer against circulating A(H3N2) virus clade. NAI titers were independently associated with lower odds of influenza A(H1N1)pdm09 and A(H3N2) after controlling for HI titer. Conclusions: Higher influenza antibody titers against circulating viruses were associated with lower likelihood of influenza virus infection among adult patients with acute respiratory illness.


  • Influenza Vaccine Effectiveness Against Outpatient Acute Respiratory Illness With Laboratory-confirmed Influenza, United States, 2024–2025 Season

    by Jessie R Chung, Ashley M Price, Stacey L House, Jamie Mills, Karen J Wernli, Magali Sanchez, Emily T Martin, Ivana A Vaughn, Vel Murugan, Joanna Kramer, et al.

    Background: Influenza A(H1N1)pdm09 and A(H3N2) viruses predominated during the 2024–2025 US influenza season. We estimated influenza vaccine effectiveness (VE) in the United States against mild-to-moderate outpatient influenza illness by influenza type and subtype in the 2024–2025 season. Methods: We enrolled outpatients aged ≥8 months with acute respiratory illness symptoms including cough from outpatient health clinics, urgent care clinics, and emergency departments in 7 states. Upper respiratory specimens were tested for influenza type/subtype by reverse-transcriptase polymerase chain reaction. Influenza VE was estimated with a test-negative design comparing odds of testing positive for influenza among vaccinated versus unvaccinated participants controlling for age, study site, underlying health status, and month of illness onset. We also estimated VE of current season vaccination among adults stratified by prior season vaccination status. Results: Among 6793 enrolled patients, 2016 (30%) tested positive for influenza including 961 A(H3N2), 770 A(H1N1)pdm09, and 183 B/Victoria. Overall VE against any influenza illness was 33% (95% confidence interval [CI]: 24 to 41): 27% (95% CI: 14 to 39) against influenza A(H3N2), 37% (95% CI: 24 to 48) against A(H1N1)pdm09, and 40% (95% CI: 12 to 59) against B/Victoria. We did not detect statistically significant interaction between current and prior season vaccination. Conclusions: Influenza vaccination during the 2024–2025 season protected against circulating influenza viruses, reducing the risk of outpatient medically attended influenza overall by approximately one-third among people who were vaccinated.


  • Open Access

    Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024–25 season

    by Jessie R. Chung, Ashley M. Price, Stacey L. House, Jamie Mills, Karen J. Wernli, Magali Sanchez, Emily T. Martin, Ivana A. Vaughn, Vel Murugan, Joanna Kramer, et al.

    Background: Influenza A(H1N1)pdm09 and A(H3N2) viruses predominated during the 2024–25 U.S. influenza season. We estimated influenza vaccine effectiveness (VE) in the United States against mild-to-moderate outpatient influenza illness by influenza type and subtype in the 2024–25 season. Methods: We enrolled outpatients aged ≥8 months with acute respiratory illness symptoms including cough in 7 states. Upper respiratory specimens were tested for influenza type/subtype by reverse-transcriptase polymerase chain reaction (RT-PCR). Influenza VE was estimated with a test-negative design comparing odds of testing positive for influenza among vaccinated versus unvaccinated participants controlling for age, study site, underlying health status, and month of illness onset. We also estimated VE of current season vaccination among adults stratified by prior season vaccination status. Results: Among 6,793 enrolled patients, 2,016 (30%) tested positive for influenza including 961 A(H3N2), 770 A(H1N1)pdm09, and 183 B/Victoria. Overall vaccine effectiveness against any influenza illness was 33% (95% Confidence Interval [CI]: 24 to 41): 27% (95% CI: 14 to 39) against influenza A(H3N2), 37% (95% CI: 24 to 48) against A(H1N1)pdm09, and 40% (95% CI: 12 to 59) against B/Victoria. VE did not differ based on whether or not participants had received influenza vaccine the previous season. Conclusions: Influenza vaccination during the 2024–25 season protected against circulating influenza viruses, reducing the risk of outpatient medically attended influenza overall by approximately one-third among people who were vaccinated. Key Points: Influenza vaccine reduced the risk of outpatient acute respiratory illness due to laboratory-confirmed influenza during the 2024–25 season by a third.

  • Open Access

    Influenza Antibody Levels Associated with Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu VE Network, November 2018–May 2019

    by Brendan Flannery, Jessie R. Chung, Crystal Holiday, Stacie Jefferson, Manjusha Gaglani, Kempapura Murthy, Richard K. Zimmerman, Mary Patricia Nowalk, Michael L. Jackson, Karen J. Wernli, et al.

    Background: We assessed associations between antibody concentrations within 7 days of symptom onset and testing positive for influenza virus infection among outpatients enrolled in a test-negative study. Methods: From November 2018─May 2019, study sites in five states obtained serum and respiratory specimens from outpatients aged ≥18 years presenting with acute respiratory illness. Respiratory specimens were tested for influenza virus, and viral clades were identified by genomic sequencing. We measured influenza antibody titers against vaccine and circulating viruses by hemagglutination inhibition (HI), microneutralization (MN) and neuraminidase inhibition (NAI) assays. Percent of patients with HI, MN and NAI titers ≥10 and ≥40 were compared among patients with and without influenza-associated illness, and reduction in odds of confirmed influenza at increasing HI, MN and NAI antibody titers was estimated using logistic regression adjusting for influenza vaccination status and time since beginning of influenza season. Results: Among 175 patients with confirmed influenza virus infection, including 112 with influenza A(H1N1)pdm09 and 63 with A(H3N2) (44 clade 3C.3a), and 130 test-negative control patients, higher antibody titers against influenza hemagglutinin or neuraminidase proteins at enrollment were associated with lower odds of influenza virus infection. HI and MN antibody titers against circulating viruses were more strongly associated with protection than titers against vaccine reference viruses. Odds of A(H1N1)pdm09 infection were 44% and 54% lower for each two-fold increase in A(H1N1)pdm09 HI or NAI titer, respectively. Odds of A(H3N2) infection were 46% and 30% lower, respectively, for each two-fold increase in MN or NAI titer against circulating A(H3N2) virus clade. NAI titers were independently associated with lower odds of influenza A(H1N1)pdm09 and A(H3N2) after controlling for HI titer. Conclusion: Higher influenza antibody titers against circulating viruses were associated with lower likelihood of influenza virus infection among adult patients with acute respiratory illness. SUMMARY: From November 2018─May 2019, we assessed the association between antibody concentrations during acute illness and laboratory-confirmed influenza among adult patients enrolled in a test-negative study in five US states. We found that higher influenza antibody titers were associated with lower likelihood of symptomatic influenza virus infection.


  • Open Access

    Estimating influenza transmission parameters: Comparing two study designs, 2023–2024

    by Jessica E. Biddle, Stacey House, Jennie H. Kwon, Rachel M. Presti, Stephanie A. Fritz, Tara Curley, Son H. McLaren, Melissa S. Stockwell, Jonathan Schmitz, H. Keipp Talbot, et al.

  • Absolute and Relative Effectiveness of Cell Culture–Based and Egg–Based Quadrivalent Inactivated Influenza (Flu) Vaccine Products From the 2014–2015 to 2018–2019 Seasons, US Flu VE Network

    by Manjusha Gaglani, Chandni Raiyani, Kempapura Murthy, Michael Smith, Briget da Graca, Gueorgui Dubrocq, Madhava Beeram, Emily T Martin, Arnold S Monto, Richard K Zimmerman, et al.

    Background: Estimates of the annual effectiveness of influenza vaccination combine multiple vaccine types. Reports of brand/product-specific vaccine effectiveness (VE) of egg-based and cell culture–based quadrivalent inactivated influenza vaccines (IIV4 and ccIIV4, respectively) are limited. Methods: Using an observational test-negative study design, we compared the effectiveness of selected IIV4 and ccIIV4 products among outpatients enrolled in the US Influenza Vaccine Effectiveness (Flu VE) Network from 2014–2015 to 2018–2019. We used multivariable logistic regression to estimate the product-specific and age group–specific absolute VE and relative VE (rVE) of recommended, age-appropriate vaccines against symptomatic laboratory-confirmed outpatient influenza. The rVE of ccIIV4 versus IIV4 products was estimated during 2 seasons from 2017–2019 among participants aged ≥4 years. Results: Pooling data from 5 influenza seasons when 18% and 15% of vaccinated patients had received Fluarix Quadrivalent or Fluzone Quadrivalent IIV4, respectively, the VE against influenza was 32% for Fluarix and 37% for Fluzone. Pooling 2 seasons when 11% and 28% of vaccinated patients had received ccIIV4 (Flucelvax Quadrivalent) and IIV4 (FluLaval Quadrivalent), respectively, the VE against influenza for each product was 30%. The absolute VE compared with unvaccinated patients was lowest against influenza A(H3N2) compared with that against A(H1N1)pdm09 and each B lineage; VE point estimates were lowest among patients aged ≥50 years compared with 2 younger age groups. The rVE estimates were not statistically significant, indicating similar protection across vaccine products. Conclusions: Comparisons of influenza vaccine products over multiple seasons showed benefit of both IIV4 and ccIIV4 against symptomatic laboratory-confirmed outpatient influenza, with similar absolute and relative levels of protection provided by each product.


  • Modeling the Potential Impacts of Outpatient Antiviral Treatment in Reducing Influenza-Associated Hospitalizations in the United States

    by Sinead E Morris, Sarabeth M Mathis, Emily Reeves, Jessie R Chung, Rebecca K Borchering, Nathaniel M Lewis, Svetlana Masalovich, Shikha Garg, Timothy M Uyeki, A Danielle Iuliano, et al.

    Background: Seasonal influenza causes an estimated 120 000 to 710 000 hospitalizations annually in the United States. Treatment with antiviral medications, such as oseltamivir, can reduce risks of hospitalization among people with influenza-associated illness. The US Centers for Disease Control and Prevention recommends initiating antiviral treatment as soon as possible for outpatients with suspected or confirmed influenza who have severe or progressive illness or are at higher risk of influenza complications. Methods: We developed a probabilistic model to estimate the impact of antiviral treatment in reducing hospitalizations among US outpatients with influenza. Parameters were informed by seasonal influenza surveillance platforms and stratified by age group and whether individuals had a condition associated with higher risk of influenza complications. We modeled different scenarios for influenza antiviral effectiveness and outpatient testing and prescribing practices, then compared our results with a baseline scenario in which antivirals were not used. Results: Across the modeled scenarios, antiviral treatment resulted in 1215 to 14 184 fewer influenza-associated hospitalizations on average when compared with the baseline scenario (0.2%–2.7% reduction). The greatest effects occurred among adults aged ≥65 years and individuals with conditions associated with higher risk of influenza complications. Modeling 50% improvements in access to care, testing, prescribing, and treatment resulted in greater potential impacts, with over 71 000 (13.3%) influenza-associated hospitalizations averted on average compared to baseline. Conclusions: Our results support recommendations to prioritize outpatient antiviral treatment among older adults and others at higher risk of influenza complications. Improving access to prompt testing and treatment among outpatients with suspected influenza could reduce hospitalizations substantially.


  • Top Cited Papers

    Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023–2024 Season

    by Jessie R Chung, Ashley M Price, Richard K Zimmerman, Krissy Moehling Geffel, Stacey L House, Tara Curley, Karen J Wernli, C Hallie Phillips, Emily T Martin, Ivana A Vaughn, et al.

    Background: The 2023–2024 US influenza season was characterized by a predominance of A(H1N1)pdm09 virus circulation with cocirculation of A(H3N2) and B/Victoria viruses. We estimated vaccine effectiveness (VE) in the United States against mild-to-moderate medically attended influenza illness in the 2023–2024 season. Methods: We enrolled outpatients aged ≥8 months with acute respiratory illness in 7 states. Respiratory specimens were tested for influenza type/subtype by reverse-transcriptase polymerase chain reaction. Influenza VE was estimated with a test-negative design comparing odds of testing positive for influenza among vaccinated versus unvaccinated participants. We estimated VE by virus subtype/lineage and A(H1N1)pdm09 genetic subclades. Results: Among 6629 enrolled patients, 1780 (27%) tested positive for influenza, including 806 with A(H1N1)pdm09, 567 with B/Victoria, and 328 with A(H3N2). VE against any influenza illness was 44% (95% confidence interval, 36%–51%): 29% (15%–41%) against influenza A(H1N1)pdm09, 74% (65%–81%) against B/Victoria, and 30% (8%–47%) against A(H3N2). Statistically significant protection against any influenza was found for all age groups except adults aged 50–64 years. Lack of protection in this age group was specific to influenza A–associated illness. We observed differences in VE by birth cohort and A(H1N1)pdm09 virus genetic subclade. Conclusions: Vaccination reduced outpatient medically attended influenza overall by 44% and provided protection overall against circulating influenza A and B viruses. Serologic studies would help inform differences observed by age groups.